
OMB APPROVAL
OMB Number:		3235-0116
Expires:	December 31, 2026
Estimated average burden
hours per response		8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2025.

Commission File Number 001-41670

Apollomics, Inc.

Not Applicable

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

~~Appointment~~Cayman ~~and~~Litigation ~~Departure~~Settlement ~~of Certain Directors~~

On November 16 19, 2025, MrApollomics Inc. ~~Po-Jen~~ ~~Hsueh~~(the ~~resigned~~“Company”) ~~from~~announced that it entered into a settlement agreement (the ~~Board~~“Settlement Agreement”) ofto ~~Directors~~fully resolve and conclude all matters (the “Settlement”) related to legal proceedings previously filed in the Grand Court of the Cayman Islands by two minority investors in the Company (the “~~Board~~Cayman Litigation”). ~~Mr. Hsueh~~As described in more detail in the Company’s ~~resignation~~Annual ~~was~~Report ~~not~~on ~~related~~Form to20-F ~~any~~for ~~disagreement~~the year ended December 31, 2024, the Cayman Litigation involved claims issued on July 22, 2024 in the Grand Court of the Cayman Islands by an investment manager on behalf of two minority investors in the Company who had requested the redemption of certain preferred shares of the Company shortly before the Company’s 2023 consummation of the public merger with Maxpro Capital Acquisition Corporation. Please refer to the Company’s press release dated November 19, 2025, furnished as Exhibit 99.1 to this Form 6-K, for more details.

~~Pursuant~~A tostay aorder ~~meeting~~had ofpreviously ~~the~~been ~~Board~~issued on ~~November~~ September 1612, 2025, ~~Dr. Ya-Chi~~as ~~(Claudia)~~disclosed ~~Huang~~in ~~was~~a ~~appointed~~previous toForm ~~the~~6-K ~~Board~~filed toon ~~fill the vacancy resulting from Mr.~~September ~~Hsueh’s~~25, ~~resignation~~2025. ~~Dr. Ya-Chi (Claudia)~~The ~~Huang~~Company ~~will~~and ~~also~~the aforementioned ~~replace~~minority ~~Mr. Po-Jen~~investors ~~Hsueh~~are asin athe ~~member~~process of submitting the ~~Company’s~~Settlement ~~Audit Committee~~ and ~~Nominating~~Settlement ~~and~~Agreement ~~Corporate~~for ~~Governance Committee. Following these changes and~~ the ~~previously announced appointments of directors, the Company~~court’s ~~Board~~approval isto ~~comprised~~conclude of the ~~following~~associated ~~seven~~litigation ~~members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang~~proceedings. ~~Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors.~~

~~Biographical~~The ~~Information~~information ofcontained in this Form 6-K relating to the ~~New~~Settlement ~~Director~~is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan’s biopharmaceutical industry.


Exhibit No.		Description

99.1		Press Release — Apollomics Announces Settlement of Cayman Litigation

~~Dr. Huang~~2 currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of ~~AngenMed~~3 ~~Therapeutics.~~

Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond’s portfolio companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities’ investment banking profits.

Dr. Huang’s scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.

Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.

Press Releases

On November 17, 2025, the Company issued a press release announcing changes to its Board and composition of committees. The press release is attached here as Exhibit 99.1.

The information contained in this Form 6-K relating to the changes in the Company’s Board of Directors is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

[EXHIBITS]

Exhibit No.		Description
99.1		Press Release - Apollomics Announces changes to its Board and composition of committees

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~APOLLOMICS INC.~~		APOLLOMICS INC.
/Date: November 17, 2025	By:	/s/ Peter Lin
			(Registrant)
	Name:	Peter Lin
Date November 19, 2025
	Title:	Chief Financial Officer
			(Signature)*
			/s/ Peter Lin
			Peter Lin, Chief Financial Officer


SEC 1815 (07-22)		Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

3 of 3

Filing Compare · Apollomics Inc.